Update on acute bacterial rhinosinusitis
Ip S, Fu L, Balk E, Chew P, DeVine D, Lau J
Record ID 32005000313
The last AHRQ report on the treatment of acute bacterial sinusitis was published in 1999. Since then, many more trials were published comparing different antibiotics not found in the previous report. In addition, universal pneumococcal vaccination was introduced in the pediatric population. It is of interest to examine the effects of these new developments on the treatment of acute bacterial rhinosinusitis.
The aim of this study was to perform a systematic review of the literature published since 1997 on comparisons of antibiotics in the treatment of acute bacterial rhinosinusitis, to summarize the adverse events and note any reported impact of pneumococcal vaccine on the treatment of acute bacterial rhinosinusitis.
Authors' results and conclusions:
Thirty-nine randomized controlled trials from 1997 to 2004 met the inclusion criteria for this report. With the exception of 5 studies that did not provide the information, all studies were either funded by pharmaceutical companies or had authors associated with the pharmaceutical industry. Only one study exclusively evaluated pediatric population. The trials evaluated pencillins, cephalosporins, macrolides, azalides, ketolides, quinolones, carbapenems and tetracyclines. In 5 placebo-controlled trials, antibiotics were more effective than placebo, reducing the risk of clinical failure by about 25-30 percent 7 to 14 days after treament initiation. Compared to amoxicillin/clavulanate, treatment with cephalosporins result in about 3.5 more clinical failures per 100 patients at 10-25 days after treatment initiation. There was no consistent difference observed when comparing amoxcillin-clavulanate, cephalosporins and quinolones to the group encompassing macrolides, azalides and ketolide.
Eight studies that evaluated different treatment durations generally found no differences in efficacy outcomes between the shorter and longer duration therapies.
Thirty-four of the comparative trials and five additional non-comparative studies reported adverse events. Descriptions of adverse events were diverse among studies. It was not possible to make meaningful comparisons of adverse event rates across different antibiotic classes given the large variation in the adverse event rates within the same antibiotic class. Overall, the most common adverse events involved the gastrointestinal and the nervous system (such as headache). We did not identify any article in our literature search that directly addressed the impact of pneumococcal vaccine on the treatment of acute bacterial rhinosinusitis.
About two-thirds of the patients with acute rhinosinusitis receiving placebos recovered without antibiotics. Antibiotics are superior to placebo in the treatment of rhinosinusitis. Amoxicillin/clavulanate is more effective than the cephalosporin class of antibiotics in the treatment of sinusitis only in the short-term follow up, with an absolute risk difference of about 3.5 percent.
There are only a few studies that specifically examined the effect of different treatment duration on outcome efficacy; they generally found no difference between shorter and longer duration of treatment. It is not possible to compare the rates of adverse events across different antibiotic classes. Severe adverse events in general are uncommon; they occurred in up to about 3.5 percent of patients in all classes of antibiotics.
As of September 2004, there have not been any published studies examining the effect of the pneumococcal vaccine on the treatment of acute sinusitis. A minority of studies were placebo controlled. In addition, from a health care cost standpoint, there were very few comparative studies between newer antibiotics and older inexpensive ones (like amoxicillin and trimethoprim/sulfamethoxazole).
English language abstract:
An English language summary is available
- Acute Disease
- Anti-Bacterial Agents
- Bacterial Infections
Agency for Healthcare Research and Quality
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Agency for Healthcare Research and Quality (AHRQ)